Tardive dyskinesia--reversible and persistent
- PMID: 35116
- DOI: 10.1001/archpsyc.1979.01780050095012
Tardive dyskinesia--reversible and persistent
Abstract
Twenty-one hospitalized patients over 50 years of age who had tardive dyskinesia were studied for 13 months. After withdrawal of neuroleptics and antidepressants for three months, dyskinetic symptoms abated in 12 patients and persisted in nine. Discriminant function analysis showed that the persistent and reversible dyskinesia groups could be clearly separated and that the best discriminator was the number of drug-free intervals. The persistent dyskinesia group had had significantly longer neuroleptic treatment (mean, 10.8 yr) and a greater number (mean, 5.6) of drug interruptions of at least two months' duration each than did the reversible dyskinesia group. Our finding, as well as the literature reviewed, does not support the commonly held notion that frequent lengthy interruptions of long-term drug treatment reduce the incidence of persistent dyskinesia, at least in patients who are otherwise predisposed to the development of tardive dyskinesia.
Similar articles
-
[Therapeutic measures in tardive dyskinesia].Fortschr Neurol Psychiatr. 1983 Jun;51(6):203-26. doi: 10.1055/s-2007-1002227. Fortschr Neurol Psychiatr. 1983. PMID: 6136457 German.
-
The treatment of tardive dyskinesia.Schweiz Arch Neurol Psychiatr (1985). 1996;147(1):13-8. Schweiz Arch Neurol Psychiatr (1985). 1996. PMID: 8685689 Review.
-
Clinical and epidemiologic aspects of tardive dyskinesia.J Clin Psychiatry. 1985 Apr;46(4 Pt 2):8-13. J Clin Psychiatry. 1985. PMID: 2858483
-
Follow-up study of 11 patients with potentially reversible tardive dyskinesia.Am J Psychiatry. 1987 Nov;144(11):1496-8. doi: 10.1176/ajp.144.11.1496. Am J Psychiatry. 1987. PMID: 2890309
-
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.J Clin Psychiatry. 2000;61 Suppl 4:21-6. J Clin Psychiatry. 2000. PMID: 10739327 Review.
Cited by
-
Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.BMJ. 1989 Apr 15;298(6679):985-90. doi: 10.1136/bmj.298.6679.985. BMJ. 1989. PMID: 2567190 Free PMC article. Clinical Trial.
-
Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys.Psychopharmacology (Berl). 1982;77(3):223-8. doi: 10.1007/BF00464570. Psychopharmacology (Berl). 1982. PMID: 6126906
-
Effects of intermittent haloperidol treatment on dopamine receptor sensitivity in guinea pigs.Psychopharmacology (Berl). 1984;84(1):98-100. doi: 10.1007/BF00432034. Psychopharmacology (Berl). 1984. PMID: 6436898
-
Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.Tremor Other Hyperkinet Mov (N Y). 2014 Oct 23;4:266. doi: 10.7916/D8MS3R8C. eCollection 2014. Tremor Other Hyperkinet Mov (N Y). 2014. PMID: 25374768 Free PMC article.
-
Bauhinia forficata prevents vacuous chewing movements induced by haloperidol in rats and has antioxidant potential in vitro.Neurochem Res. 2013 Apr;38(4):789-96. doi: 10.1007/s11064-013-0981-8. Epub 2013 Feb 2. Neurochem Res. 2013. PMID: 23377855
MeSH terms
Substances
LinkOut - more resources
Full Text Sources